DVLP Medicines digitizes drug development by converting drug assets and workflows into secure digital formats on a blockchain platform, enabling real-time data management and automated funding through intelligent contracts. This approach addresses the high costs and complexities of traditional drug development, allowing more promising molecules to advance to clinical trials.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug development is expensive and complex, limiting the number of promising molecules that can advance to clinical trials. The high costs and intricate processes often sideline potentially effective therapies, not because of their inefficacy, but due to financial and logistical constraints.
Solution
DVLP Medicines is building a platform to digitize and streamline drug development, converting drug assets and workflows into secure digital formats. This approach aims to reduce the barriers to entry, enabling more molecules to progress through the development pipeline. The platform facilitates collaboration between stakeholders in finance, research, and development, fostering a marketplace where resources can be efficiently allocated to promising drug candidates. By digitizing drug assets and automating key processes with AI and blockchain technology, DVLP Medicines seeks to accelerate the development timeline and reduce overall costs. The platform utilizes Asset-Focused Organizations (AFOs) to manage individual drug assets in a decentralized and integrated manner.
Target Audience
The primary target audience includes drug discovery companies with promising molecules, investors seeking opportunities in drug development, and researchers and vendors involved in the drug development process.
Features
- Digitization of drug assets, converting files, IP, and molecule history into a secure digital format.
- AI-driven automation of the end-to-end development process, guiding drugs along a common path with regulatory guardrails.
- Embedded finance capabilities that fractionalize funding throughout the development lifecycle.
- Secure intelligent contracts to automatically facilitate every step of a drug's development.
- Real-time data updates, resulting in a data-driven asset ready for regulatory evaluation.
- Asset-Focused Organizations (AFOs) dedicated to moving a single drug asset forward.